Phytogenic polyphenols as glycogen phosphorylase inhibitors: The potential of triterpenes and flavonoids for glycaemic control in type 2 diabetes

George A. Stravodimos, Ben A. Chetter, Efthimios Kyriakis, Anastassia L. Kantsadi, Demetra S.M. Chatzileontiadou, Vassiliki T. Skamnaki, Atsushi Kato, Joseph M. Hayes, Demetres D. Leonidas

Research output: Contribution to journalReview ArticleResearchpeer-review

17 Citations (Scopus)


Glycogen phosphorylase (GP) is a validated pharmaceutical target for the development of antihyperglycaemic agents. Phytogenic polyphenols, mainly flavonoids and pentacyclic triterpenes, have been found to be potent inhibitors of GP. These compounds have both pharmaceutical and nutraceutical potential for glycemic control in diabetes type 2. This review focuses mainly on the most successful (potent) of these compounds discovered to date. The protein-ligand interactions that form the structural basis of their potencies are discussed, highlighting the potential for exploitation of their scaffolds in the future design of new GP inhibitors.

Original languageEnglish
Pages (from-to)384-403
Number of pages20
JournalCurrent Medicinal Chemistry
Issue number4
Publication statusPublished - 1 Feb 2017
Externally publishedYes


  • Alpha-glucosidases
  • Antioxidants
  • Diabetes
  • Flavonoids
  • Glycogen phosphorylase
  • Pentacyclic triterpenes

Cite this